B3936

BAY R3401

≥98% (HPLC), solid

• Synonym(e): 4-(2-Chlorophenyl)-1-ethyl-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylic acid isopropyl ester
• Empirische Formel (Hill-System): C₂₀H₂₂ClNO₄
• CAS-Nummer: 100276-03-7
• Molekulargewicht: 375.85
• NACRES: NA.77
• PubChem Substance ID: 24891741
• UNSPSC Code: 12352200
• MDL number: MFCD08705409
• Assay: ≥98% (HPLC)
• Form: solid

Eigenschaften

• assay: ≥98% (HPLC)
• form: solid
• color: white
• solubility: DMSO: 15 mg/mL
• originator: Bayer
• storage temp.: 2-8°C
• SMILES string: CCN1C(C)=C(C(c2ccccc2Cl)C3=C1COC3=O)C(=O)OC(C)C
• InChI: 1S/C20H22ClNO4/c1-5-22-12(4)16(20(24)26-11(2)3)17(13-8-6-7-9-14(13)21)18-15(22)10-25-19(18)23/h6-9,11,17H,5,10H2,1-4H3
• InChI key: NPUSXSOBPNHOPH-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

BAY R3401 is a glycogen phosphorylase inhibitor. The racemic prodrug, BAY R3401, suppresses hepatic glycogenolysis. BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. It has been investigated that the metabolites of BAY R3401 suppress hepatic glycogenolysis by allosteric inhibition and dephosphorylation of phosphorylase a.

Glycogen phosphorylase inhibitor.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Light sensitive; store in amber vials.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• Gefahrencodes: H302
• Sicherheitshinweise: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• PSA (Persönliche Schutzausrüstung): dust mask type N95 (US), Eyeshields, Gloves